AIDS and HIV prevention continues to improve over time with promising discoveries. The currently used Pre-Exposure Prophylaxis (PrEP) may soon be replaced by a more efficient new drug known as cabotegravir (CAB).

The University Of Cincinnati College Of Medicine, headed by Dr. Carl Fichtenbaum, is currently making testing the CAB drug. As of writing, cabotegravir is undergoing stage three of the drug development procedure. Volunteers are now being accepted to thoroughly check the efficacy of the drug in preventing the proliferation of HIV.

Like Us on Facebook

The main point of the research and drug development is to improve how HIV and AIDS are being prevented. The most commonly used method for HIV prevention is the use of Pre-Exposure Prophylaxis (PrEP), which is presented in the form of a pill that should be taken consistently, according to Center for Disease Control and Prevention.

In summary, PrEP is a means through, which people who are not infected with HIV but at substantial risk, can be prevented from contracting the disease. Based on research, the regular use of Prep has been shown to reduce the risk of HIV infection by up to 92 percent. Thus, combined with condoms, PrEP is considered as a powerful method to prevent the proliferation of the dreaded disease.

However, the main concern for the use of PrEP is its intake requirement, as it should regularly be taken as an ordinary pill. However, some individuals tend to forget or lack access to the pill. That is why with the help of CAB, such concerns will finally be addressed.

"They are taking the steps to prevent unwanted HIV prevention without remembering to take a pill every day because people forget to take their pills. It needs to be effective and it works," The News Record quoted Dr. Fichtenbaum saying.

Although the latest drug for HIV prevention may sound promising, tests are still being done before mass distribution. Experts are still checking whether such injectable would be as effective as a PrEP method.

"We hope to complete the enrollment on time and hope to be able to educate a lot of people in the community about HIV prevention and bend the curve of the epidemic. We want the numbers to drop," added Fichtenbaum.

Watch a discussion concerning Pre-Exposure Prophylaxis (PrEP) below: